Trillium Therapeutics (Trillium Therapeutics) EPS (Basic) : $-0.51 (TTM As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics EPS (Basic)?

Trillium Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2021 was $-0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.51.

Trillium Therapeutics's EPS (Diluted) for the three months ended in Sep. 2021 was $-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.51.

Trillium Therapeutics's EPS without NRI for the three months ended in Sep. 2021 was $-0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2021 was -0.51.

During the past 3 years, the average EPS without NRI Growth Rate was 42.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Trillium Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 61.00% per year. The lowest was -49.80% per year. And the median was 16.65% per year.

Trillium Therapeutics EPS (Basic) Historical Data

The historical data trend for Trillium Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics EPS (Basic) Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EPS (Basic)

Get a 7-Day Free Trial

-3.02

-3.67

-2.35

-1.15

-0.70

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
EPS (Basic)	Get a 7-Day Free Trial															-0.14	-0.04	-0.11	-0.18	-0.18

Trillium Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Trillium Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2020 is calculated as

Basic EPS (A: Dec. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-59.346	-	0)	/	84.601
	=	-0.70

Trillium Therapeutics's Basic EPS for the quarter that ended in Sep. 2021 is calculated as

Basic EPS (Q: Sep. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-19.316	-	0)	/	104.855
	=	-0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51

Trillium Therapeutics (NAS:TRIL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Trillium Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.